Free delivery from 300 Francs
Over 30 years of experience
Individual financing options
ISO 13485 certified since 1997
Axonlab Logo
  • Blog
  • Devices & Instruments (547)
  • Reagents & Chemicals (4'443)
  • Controls & Calibrators (181)
  • Consumables (2'444)
  • Accessories (886)
  • Rapid Tests (88)

Jump to sections

  • Medical practices
  • Labsoftware axonio
  • Practice Software
  • Pharmacies area
  • Snibe diagnostic
  • Point-of-Care (POCT)

Antigen meets PCR: two methods, one goal – the right diagnosis at the right time

  • 5 Minutes to read
  • Written by Axon Lab AG
  • General Practice

Respiratory infections caused by influenza, RSV, SARS-CoV-2 and other pathogens often produce similar symptoms and are difficult to distinguish clinically. The COVID-19 pandemic has further highlighted the importance of fast and reliable diagnostic methods.

 

Before the pandemic: clinical assessment and targeted rapid tests

Before the COVID-19 pandemic, the diagnosis of respiratory infections in primary care was often based initially on clinical assessment.

In addition, point-of-care rapid tests were available for individual pathogens, such as influenza A/B, RSV or group A streptococci. They were easy to perform, relatively inexpensive and provided diagnostic guidance within a few minutes.

Their main limitation, however, was the limited range of detectable pathogens and, compared with molecular methods, an often lower sensitivity. Particularly at low pathogen loads, a negative antigen result could miss an existing infection.

For more sensitive molecular diagnostics, samples were typically sent to a central laboratory.

This created a classic trade-off:

A quick decision on site – or more sensitive diagnostics in the laboratory.

 

During the pandemic: PCR becomes the key molecular detection method

SARS-CoV-2 fundamentally changed the situation. PCR became established as an important method for the sensitive detection of SARS-CoV-2, while rapid antigen tests were widely used, particularly for screening and point-of-care applications, thanks to their ease of use and short test time.

The pandemic showed that speed alone is not always enough. At low viral loads, antigen tests can miss infections, whereas molecular tests offer higher sensitivity.

At the same time, it became clear that diagnostic results must be available reliably and quickly for clinical decision-making.

 

After the pandemic: molecular diagnostics comes to the patient

After the pandemic, molecular diagnostics remains an important part of respiratory diagnostics. A key development in this context is the miniaturisation and automation of molecular test methods.

Modern POCT PCR systems bring molecular diagnostics closer to where clinical decisions are made – for example in the emergency department, outpatient clinic, doctor’s practice or directly in the laboratory.

This makes it possible to combine the high sensitivity of molecular methods with a short turnaround time.

As a result, the diagnostic workflow is changing:

The sample no longer has to go to the laboratory – molecular diagnostics is increasingly coming to the sample.

 

From single-pathogen testing to multiplex diagnostics

Modern multiplex PCR systems can simultaneously detect and differentiate several relevant respiratory pathogens from a single sample, for example:

  • Influenza A/B
  • RSV
  • SARS-CoV-2
  • Mycoplasma pneumoniae
  • Bordetella pertussis

This shifts the key question

from “Which pathogen should I test for?”
to “Which pathogen is causing this respiratory syndrome?”

 

Rapid antigen tests and POCT PCR – different strengths

Rapid antigen tests and POCT PCR are therefore not necessarily competitors. Both methods have their place and address different diagnostic requirements.

The rapid antigen test remains attractive where ease of use, fast availability and low costs are the priority.

POCT PCR offers advantages when a fast and at the same time highly sensitive result is relevant for a clinical or organisational decision – especially when several possible pathogens need to be differentiated.

 

Conclusion

The development of respiratory diagnostics can be described, in simplified terms, as a transition:

from “fast on site or sensitive in the laboratory”
to “fast and sensitive at the point of clinical decision-making”

 

The aim is not to replace antigen tests with PCR. Rather, diagnostic options are evolving: from clinical assessment and targeted single tests, through centralised molecular diagnostics, to automated, syndromic multiplex PCR directly at the point of care.

The combination of multiplexing, automation, high sensitivity and short turnaround time is therefore a key trend in modern respiratory diagnostics.

Popular posts
  • Instructions for downloading quality control data sheets
    Jeanette Fehlmann
  • CRP – a biomarker of viral and bacterial infections
  • CRP measurement with Microsemi CRP & Microsemi CRP LC-767
    Jeanette Fehlmann
Blog categories
  • Corporate
  • Hospital
  • Pharmacy
  • Life Science
  • General Practice
  • Molecular Diagnostics
  • Microbiology

Links

  • About us
  • What we do
  • We introduce ourselves
  • Social Responsibility
  • Jobs
  • Events
  • Blog
  • Downloads
  • Support & Helpline
  • GTC
  • Privacy Policy
  • Legal Notice
  • Shipping- & Payment conditions
  • Certificate
  • FAQ
  • Startup Lab Program

Go to Support Center

  • 0848 00 29 66
  • Monday - Friday
  • 8 a.m. - 5 p.m.
  • Go to Support Center

Contact

  • Axon Lab AG
  • Täfernstrasse 15
  • 5405 Baden-Dättwil
  • +41 56 484 80 80
  • info@axonlab.ch

Newsletter

All prices are in CHF plus VAT and shipping costs and possibly cash on delivery charges, unless otherwise described.